Skip to content

Talimogene laherparepvec

Imlygic (talimogene laherparepvec) is a gene pharmaceutical. Talimogene laherparepvec was first approved as Imlygic on 2015-12-16. It is used to treat melanoma in the USA. It has been approved in Europe to treat melanoma.
Trade Name Imlygic
Common Name Talimogene laherparepvec
Indication melanoma
Drug Class
Talimogene laherparepvec
Get full access now